Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-803 + Gemcitabine + Nab-paclitaxel in Advanced Pancreatic Cancer
NCT02559674Phase 1Completed
- Sponsor
- Altor BioScience Corporation
- Start
- Jul 2016
- Primary completion
- Feb 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept in pancreatic cancer (PC), sponsored by Altor BioScience Corporation. Primary endpoints: Maximum Tolerated Dose at 9 months, Safety Profile (Number and severity of treatment related AEs) at 48 months and 1 more. Started Jul 2016; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02559674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559674.